Quality Analysis of Autologous Platelet-Rich Plasmapheresis

• Published in: Indian journal of hematology & blood transfusion 2022-10, Vol.38 (4), p.726-730
• Main Authors: Song, Nali, Yi, Zhongmei, Ruan, Qianying, Li, Chenchen, Song, Min, Zhang, Bin
• Format: Article
• Language: English
• Subjects: Apheresis; Blood; Blood Transfusion Medicine; Hematology; Human Genetics; Medicine; Medicine & Public Health; Oncology; Original; Original Article; Patient safety; Plasma; Quality of care; Side effects
• ISSN: 0971-4502; 0974-0449; 0974-0449; 0971-4502
• DOI: 10.1007/s12288-022-01529-x

To summarized the technology of autologous platelet-rich plasmapheresis and analyzed the product quality, in order to provide safe and effective product guarantee service for clinical treatment. Technical parameters were set according to patient age, weight, height, and preoperative routine blood indices. Autologous platelet-rich plasma (PRP) was collected, and the product quality and adverse reactions of patients were statistically analyzed. Autologous PRP had platelet (PLT), white blood cell (WBC), and red blood cell (RBC) counts of (1250.26 ± 435.88) × 10 9 /L, (1.19 ± 1.95) × 10 9 /L, and (0.05 ± 0.04) × 10 12 /L, respectively. The PLT enrichment ratio in PRP was 5.66 ± 1.66. There was no significant difference in PLT, RBC, WBC, or hematocrit before and after apheresis ( P  > 0.05). The incidence of adverse reactions was 8%, and all were mild. When clinical patients use PRP in the treatment of diseases, autologous platelet-rich plasmapheresis technology was used to apheresis PRP, which has good product quality and few adverse reactions, and thus can be adopted more widely.